Dec 13, 2023, 16:21
Miloš Miljković: Our analysis of cancer drug “novelty” and cost
Miloš Miljković, Chief Medical Officer at Cartesian Therapeutics, shared a post by JAMA Network Open on Twitter, adding the following:
“As follow-up to our analysis of cancer drug efficacy versus cost, here is a look at the association between their “novelty” and cost. With Jordan Tuia, Timothée Olivier, Alyson Haslam, and Vinay Prasad.”
Quoting JAMA Network Open:
“Findings of this study indicate that the median annual price of anticancer drugs in the US is not associated with the novelty of their mechanism of action.”
For details click here.
Source: Miloš Miljković/Twitter and JAMA Network Open/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 21, 2024, 06:49
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12